Perioperative sintilimab plus chemo for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by a biopsy.
- Your tumor is in the middle or lower part of the esophagus and has been assessed as removable by a surgeon.
- Your cancer has not spread to distant organs (M0) and falls within specific stages (cT2-4aN0-3 or cT1N+).
- You can eat semi-liquid food, and have not lost more than 20% of your body weight in the last 6 months.
- You are in good overall health (ECOG score 0 or 1) and have adequate organ function for chemotherapy and surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.